• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Allergan slides on breast implant-cancer link

Allergan slides on breast implant-cancer link

January 26, 2011 By MassDevice staff

AGN logo

Shares of Allergan Inc. (NYSE:AGN) stock were down nearly 2 percent after a Food & Drug Administration review found that women with breast implants have a greater chance of contracting a rare form of cancer.

The federal watchdog agency warned doctors and patients of a possible link between saline- and silicone gel-filled breast implants and anaplastic large-cell lymphoma, a very rare type of cancer.

Patients who received the implants may have a “very small but significant risk of ALCL in the scar capsule adjacent to the implant,” according to the FDA. Thirty-four cases were reported in women with breast implants in the U.S. with about 60 reported globally since 1997,according to the FDA

Irvine, Calif.-based Allergan’s Natrelle gel and saline breast implant line essentially controls the breast implant market, along with Johnson & Johnson (NYSE:JNJ) unit Mentor Corp. Shares of JNJ held up slightly better, with trading off half a percent in late-day trading.

Shares of Allergan closed yesterday at $72.08 per share, about $2 off a 52-week high of $74.94. The company is set to announce its fourth-quarter and year-end results Feb. 2.

Doctors diagnose ALCL in roughly one of 500,000 women each year in the U.S.; ALCL in breast tissue is found in only about three of every 100 million women without breast implants, according to the FDA.

"We need more data and are asking that healthcare professionals tell us about any confirmed cases they identify,” Center for Devices and Radiological Health chief scientist Dr. William Maisel said in prepared remarks.

The FDA is not recommending that women with implants seek medical care outside their routine, but physicians should consider the possibility of ALCL in patients with late-onset cancer symptoms, the agency said. The FDA is working with the American Society of Plastic Surgeons to build a breast implant registry to help track ALCL in women with implants.

The FDA cleared breast implants for cosmetic surgery in 2006, after 14 years of limiting them to reconstructive purposes. The devices were introduced into the U.S. in 1962.

Filed Under: Business/Financial News, Cosmetic/Aesthetic, Implants, News Well Tagged With: Allergan, Breast Cancer

More recent news

  • Cooper Companies continues to see activist pressure to sell divisions, replace CEO
  • Cordis earns FDA nod for Selution SLR drug-eluting balloon
  • Siemens Healthineers links with Novo to advance liver fibrosis blood test
  • GE HealthCare rolls out AI software for predicting care bottlenecks
  • Wandercraft’s self-balancing Eve exoskeleton begins US launch

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy